Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Kangfuxin enteric-coated capsules in mild to moderate active ulcerative colitis
CTR20254279Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2025
- Countries
- 1
01
Overview
A Phase 3 trial of kangfuxin enteric-coated capsule in autoimmune colitis, sponsored by Hengrui Therapeutics. Started Dec 2025; status: active.
02
Drugs
kangfuxin enteric-coated capsule
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20254279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254279.